TransMedics Group (NASDAQ:TMDX) Price Target Raised to $117.00

TransMedics Group (NASDAQ:TMDX – Free Report) had its price target lifted by Canaccord Genuity Group from $102.00 to $117.00 in a research note published on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. Several other analysts also recently issued reports on the company. Morgan Stanley upped their price objective […]

Related Keywords

United States ,Jamesr Tobin ,Piper Sandler ,Zurcher Kantonalbank Zurich Cantonalbank ,Waleedh Hassanein ,Insider Activity At Transmedics Group ,Jpmorgan Chase Co ,News Ratings For Transmedics Group Daily ,Transmedics Group Stock Performance ,Mirae Asset Global Investments Co ,Transmedics Group ,Analyst Recommendations For Transmedics Group ,Jw Cole Advisors Inc ,York Mellon Corp ,Canaccord Genuity Group ,Shariaportfolio Inc ,Transmedics Group Company Profile ,Securities Exchange Commission ,Morgan Stanley ,Hedge Funds Weigh In On Transmedics Group ,Transmedics Group Inc ,Free Report ,Moderate Buy ,Medics Group ,Get Free Report ,Director James ,Exchange Commission ,New York Mellon Corp ,Kantonalbank Zurich Cantonalbank ,Mirae Asset Global Investments ,Asset Global Investments ,Organ Care System ,Transmedics Group Daily ,Nasdaq Tmdx ,Tmdx ,Medical ,Boost Price Target ,Canaccord Genuity Group Inc ,